Free Trial
OTCMKTS:NEXI

NexImmune Q1 2024 Earnings Results & Report

NexImmune logo

NexImmune reported Q1 2024 earnings on May 20, 2024. The company reported EPS of -$2.21.

Earnings Announcement Details

Quarter
Q1 2024
Report Date

NexImmune EPS Results

Actual EPS
-$2.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

NexImmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

NexImmune's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

NexImmune Q1 2024 Earnings FAQ

NexImmune (OTCMKTS:NEXI) reported earnings of -$2.21 per share for Q1 2024. The report was announced on Monday, May 20, 2024.

NexImmune's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for NexImmune on the company's earnings history page.

NexImmune Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
NexImmune moves forward with wind-down process
NEXI Stock Alert: NexImmune Delists From Nasdaq
See More NexImmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NexImmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NexImmune and other key companies, straight to your email.

About NexImmune

NexImmune (OTCMKTS:NEXI) was a biotechnology company focused on developing cell-based immunotherapies for cancer. Its Artificial Immune Modulation (AIM) platform was designed to activate and expand T cells that recognize specific cancer-associated targets.

The company’s investigational programs included NEXI-001, a T-cell therapy for acute myeloid leukemia, and NEXI-002, a program for multiple myeloma. NexImmune was based in Gaithersburg, Maryland, and its therapies were in clinical development rather than commercially available.

NexImmune later discontinued operations and filed for Chapter 7 bankruptcy in 2023. Its programs should therefore be understood as historical development efforts, not as an indication of current commercial services.

View NexImmune Profile